The MCCC1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Raji B lymphocyte suspension line, designed for targeted disruption of the MCCC1 gene. This polyclonal format provides a heterogeneous pool of gene-edited cells, minimizing clonal artifacts and offering a robust loss-of-function model for investigating leucine catabolism and mitochondrial carboxylase biology. The product is immediately available for functional studies without the need for single-cell cloning, ensuring rapid experimental deployment.
Raji cells are a well-established B lymphocyte model originating from a Nigerian patient with Burkitt lymphoma. These suspension lymphoblastoid cells maintain characteristic B cell features, including surface immunoglobulin expression, active B cell receptor signaling, and Epstein-Barr virus (EBV) latency, making them a standard platform for studying B cell biology, lymphoma pathogenesis, and viral oncogenesis. Their rapid proliferation and genetic tractability facilitate reproducible metabolic and pharmacological assays.
The MCCC1 gene encodes the alpha subunit of 3-methylcrotonyl-CoA carboxylase (MCC), a biotin-dependent mitochondrial enzyme that catalyzes the carboxylation of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA, a committed step in leucine degradation. This reaction lies within the branched-chain amino acid catabolic pathway and intersects the mevalonate pathway via HMG-CoA, supplying acetyl-CoA and acetoacetate for energy production and lipid synthesis. MCCC1 function is regulated upstream by PPARGC1A-mediated mitochondrial biogenesis, mTORC1 nutrient sensing, and biotin availability. The active MCC holoenzyme requires interaction with the MCCC2 beta subunit and covalent biotin attachment. Downstream, MCCC1 activity influences HMG-CoA lyase?Cmediated generation of acetyl-CoA and mevalonate pathway intermediates, thereby linking leucine metabolism to cellular energetics and isoprenoid biosynthesis.
In Raji B lymphoma cells, MCCC1 disruption eliminates 3-methylcrotonyl-CoA carboxylase activity, blocking the conversion of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA. This leads to accumulation of upstream metabolites and attenuates the supply of acetyl-CoA and HMG-CoA, potentially impairing mitochondrial function and lipid homeostasis. Given the reliance of many lymphomas on branched-chain amino acid catabolism for growth and survival, this polyclonal knockout model offers a powerful system to dissect metabolic vulnerabilities in B cell malignancies. It also enables exploration of how EBV latency and B cell receptor signaling intersect with leucine degradation pathways and mitochondrial metabolism.
These MCCC1 knockout polyclonal Raji cells are suited for modeling 3-methylcrotonyl-CoA carboxylase deficiency, characterizing leucine catabolic flux, and screening for MCC inhibitors. Assays include LC-MS metabolomics, MCC activity measurements, Seahorse mitochondrial stress tests, MTT viability under leucine deprivation, and Western blot/RT-qPCR. Additional uses cover biotin-dependent carboxylase biology, metabolic adaptations in lymphoma, and mevalonate pathway crosstalk. For further details, contact Ascent Research.
